MA29634B1 - Heterocycles condenses avec la 1,4-dihydropyridine, procede pour preparer ceux-ci, utilisation et compositions contenant ceux-ci - Google Patents

Heterocycles condenses avec la 1,4-dihydropyridine, procede pour preparer ceux-ci, utilisation et compositions contenant ceux-ci

Info

Publication number
MA29634B1
MA29634B1 MA30580A MA30580A MA29634B1 MA 29634 B1 MA29634 B1 MA 29634B1 MA 30580 A MA30580 A MA 30580A MA 30580 A MA30580 A MA 30580A MA 29634 B1 MA29634 B1 MA 29634B1
Authority
MA
Morocco
Prior art keywords
same
dihydropyridine
preparing
compositions containing
heterocycles
Prior art date
Application number
MA30580A
Other languages
English (en)
Inventor
Jacques Mauger
Anil Nair
Nina Ma
Kirsten Bjergarde
Bruno Filoche-Romme
Odile Angouillant-Boniface
Serge Mignani
Cecile Combeau
Jean-Christophe Carry
Francois Clerc
Herve Minoux
Laurent Schio
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MA29634B1 publication Critical patent/MA29634B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne des hétérocycles condensés avec la 1,4-dihydropyridine, un procédé pour préparer ceux-ci, l'utilisation et des compositions contenant ceux-ci. L'invention concerne des hétérocycles condensés avec la dihydropyridine substitués utiles pour le traitement d'une maladie cancéreuse, en particulier pour empêcher des cellules cancéreuses de se diviser. Ces composés agissent en tant qu'inhibiteurs des kinases Aurora A et/ou B.
MA30580A 2005-07-20 2008-01-16 Heterocycles condenses avec la 1,4-dihydropyridine, procede pour preparer ceux-ci, utilisation et compositions contenant ceux-ci MA29634B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05291558A EP1746097B1 (fr) 2005-07-20 2005-07-20 Héterocyles à fusion1,4-dihydropyridineprocédé de préparation, utilisation et compositions de celles-ci

Publications (1)

Publication Number Publication Date
MA29634B1 true MA29634B1 (fr) 2008-07-01

Family

ID=35510894

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30580A MA29634B1 (fr) 2005-07-20 2008-01-16 Heterocycles condenses avec la 1,4-dihydropyridine, procede pour preparer ceux-ci, utilisation et compositions contenant ceux-ci

Country Status (37)

Country Link
US (1) US8163768B2 (fr)
EP (2) EP1746097B1 (fr)
JP (2) JP2009501778A (fr)
KR (1) KR101286796B1 (fr)
CN (1) CN101243087B (fr)
AR (1) AR054845A1 (fr)
AT (2) ATE455115T1 (fr)
AU (1) AU2006273692B8 (fr)
BR (1) BRPI0614002A2 (fr)
CA (1) CA2615700C (fr)
CR (1) CR9663A (fr)
CY (1) CY1109964T1 (fr)
DE (1) DE602005018911D1 (fr)
DK (1) DK1746097T3 (fr)
DO (1) DOP2006000175A (fr)
EA (1) EA016815B1 (fr)
EC (1) ECSP078062A (fr)
ES (1) ES2339676T3 (fr)
HN (1) HN2008000088A (fr)
HR (1) HRP20100195T1 (fr)
IL (1) IL188861A0 (fr)
MA (1) MA29634B1 (fr)
MX (1) MX2008000902A (fr)
MY (1) MY148617A (fr)
NO (1) NO20080831L (fr)
NZ (1) NZ592766A (fr)
PE (2) PE20070212A1 (fr)
PL (1) PL1746097T3 (fr)
PT (1) PT1746097E (fr)
RS (1) RS51351B (fr)
SI (1) SI1746097T1 (fr)
TN (1) TNSN08020A1 (fr)
TW (1) TWI386411B (fr)
UA (1) UA98928C2 (fr)
UY (1) UY29685A1 (fr)
WO (1) WO2007012972A2 (fr)
ZA (1) ZA200800542B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945535B1 (fr) * 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
FR2967413A1 (fr) * 2010-11-17 2012-05-18 Sanofi Aventis Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.
CN104334529B (zh) 2012-05-15 2017-03-15 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物
CA2871715A1 (fr) 2012-05-15 2013-11-21 Novartis Ag Derives de benzamide pour inhiber l'activite d'abl1, d'abl2 et de bcr-abl2
NZ701626A (en) 2012-05-15 2016-02-26 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
JP6078640B2 (ja) 2012-05-15 2017-02-08 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
EP2909204B1 (fr) 2012-10-12 2018-12-05 The Broad Institute, Inc. Inhibiteurs de gsk3 et leurs procédés d'utilisation
CA2968884A1 (fr) 2014-12-10 2016-06-16 Massachusetts Institute Of Technology Derives fusionnes de 1,3-azole utiles pour le traitement de maladies proliferatives
EP4212532A3 (fr) 2015-04-30 2023-09-27 Memorial Sloan Kettering Cancer Center Analogues de la mitragynine et leurs utilisations
RU2619932C1 (ru) * 2015-11-25 2017-05-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный университет" (ФГБОУ ВО "ВГУ") ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДО[3,4-е]ПИРИМИДИНЫ И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ
WO2017124087A1 (fr) 2016-01-15 2017-07-20 Memorial Sloan-Kettering Cancer Center Composés antiparasitaires et leurs utilisations
US10106555B2 (en) 2016-02-16 2018-10-23 Massachusetts Institute Of Technology Max binders as MYC modulators and uses thereof
US11203601B2 (en) 2017-04-05 2021-12-21 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043998B1 (fr) * 1997-12-13 2007-03-07 Bristol-Myers Squibb Company UTILISATION DE PYRAZOLO [3,4-b]PYRIDINE EN TANT QU'INHIBITEURS DE KINASE DEPENDANT DE LA CYCLINE
JP2003529552A (ja) 1999-11-19 2003-10-07 アボット・ラボラトリーズ 三環性ジヒドロピリミジンカリウムチャンネル開口剤
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
CA2402179A1 (fr) 2000-03-03 2001-09-13 Abbott Laboratories Agents ouvrant les canaux potassium a base de dihydropyrazolone tricyclique et de dihydroisoxazolone tricyclique
WO2002062795A2 (fr) 2001-02-02 2002-08-15 Mitsubishi Pharma Corporation Composes de dihydropyrazolopyridine et leur utilisation pharmaceutique
FR2823854A1 (fr) 2001-04-18 2002-10-25 Centre Nat Rech Scient Nouveau procede de criblage d'inhibiteurs de la liaison entre la proteine oxyde nitrique synthase neuronale et la proteine inhibitrice de l'oxyde nitrique synthase neuronale
FR2825091B1 (fr) * 2001-05-23 2003-07-04 Servier Lab Nouveaux derives tricycliques de dihydro-quinnoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7037902B2 (en) * 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
SE0301371D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab New Compounds
CN1823067A (zh) * 2003-06-13 2006-08-23 赞塔里斯有限公司 具有抑制磷脂酰肌醇3－激酶活性的化合物及其使用方法

Also Published As

Publication number Publication date
US20080261969A1 (en) 2008-10-23
NZ592766A (en) 2012-12-21
PT1746097E (pt) 2010-04-15
HRP20100195T1 (hr) 2010-05-31
MX2008000902A (es) 2008-03-26
UA98928C2 (ru) 2012-07-10
DE602005018911D1 (de) 2010-03-04
ZA200800542B (en) 2010-02-24
UY29685A1 (es) 2007-02-28
BRPI0614002A2 (pt) 2011-03-01
CR9663A (es) 2008-02-21
CA2615700A1 (fr) 2007-02-01
SI1746097T1 (sl) 2010-05-31
ATE521611T1 (de) 2011-09-15
HN2008000088A (es) 2011-05-31
TWI386411B (zh) 2013-02-21
MY148617A (en) 2013-05-15
EA200800374A1 (ru) 2008-08-29
ATE455115T1 (de) 2010-01-15
PL1746097T3 (pl) 2010-06-30
CA2615700C (fr) 2013-06-18
CY1109964T1 (el) 2014-09-10
TNSN08020A1 (en) 2009-07-14
KR20080026658A (ko) 2008-03-25
WO2007012972A3 (fr) 2007-04-05
CN101243087B (zh) 2013-07-24
DOP2006000175A (es) 2007-03-31
EP1910366A2 (fr) 2008-04-16
PE20100718A1 (es) 2010-10-20
ES2339676T3 (es) 2010-05-24
ECSP078062A (es) 2008-01-23
CN101243087A (zh) 2008-08-13
JP2013063987A (ja) 2013-04-11
IL188861A0 (en) 2008-04-13
US8163768B2 (en) 2012-04-24
AU2006273692B8 (en) 2012-12-13
AU2006273692A1 (en) 2007-02-01
EP1746097B1 (fr) 2010-01-13
AR054845A1 (es) 2007-07-18
AU2006273692B2 (en) 2012-11-22
JP2009501778A (ja) 2009-01-22
EA016815B1 (ru) 2012-07-30
PE20070212A1 (es) 2007-03-21
RS51351B (en) 2011-02-28
DK1746097T3 (da) 2010-05-25
TW200740812A (en) 2007-11-01
EP1910366B1 (fr) 2011-08-24
KR101286796B1 (ko) 2013-07-17
NO20080831L (no) 2008-04-03
AU2006273692A8 (en) 2012-12-13
EP1746097A1 (fr) 2007-01-24
WO2007012972A2 (fr) 2007-02-01

Similar Documents

Publication Publication Date Title
MA29634B1 (fr) Heterocycles condenses avec la 1,4-dihydropyridine, procede pour preparer ceux-ci, utilisation et compositions contenant ceux-ci
TN2009000450A1 (fr) Derives de pyridine
MA47079A (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
TNSN07022A1 (fr) Derives de pyridine
MA29652B1 (fr) 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
TN2011000316A1 (fr) Derives de sulfonamides
MA29926B1 (fr) Derives de pyrazine
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
MA29480B1 (fr) Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
MY148479A (en) Piperidinyl-substituted isoquinolone derivatives
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
MY146644A (en) Cyclohexylamin isoquinolone derivatives
TW200635918A (en) Pharmaceutical compounds
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA31655B1 (fr) Pyrimidines cyclopenta [d] hydroxylés et méthoxylés utilisés en tant qu'inhibiteurs de la protéine kinase akt.
MA31586B1 (fr) Dérivés d'alcools alkyliques de 1-phényl-2-pyridinyle en tant qu'inhibiteurs de la phosphodiestérase
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
MA30405B1 (fr) Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3
NO20061791L (no) Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin
SE0301368D0 (sv) Chemical compounds